Landfar Bio-medicine Co., Ltd (SHE:000504)
China · Delayed Price · Currency is CNY 8.85
-0.45 (-4.84%)
At close: Jan 23, 2026
Landfar Bio-medicine Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | -6.2 | -19.85 | -28.17 | -12.46 | -19.13 | 8.15 | Upgrade |
Depreciation & Amortization | 5.7 | 5.7 | 6.34 | 6.21 | 6.87 | 3.35 | Upgrade |
Other Amortization | 12.19 | 12.19 | 9.15 | 9.1 | 7.26 | 0.44 | Upgrade |
Loss (Gain) From Sale of Assets | -0.16 | -0.16 | -11.9 | -0.08 | -0.03 | -1.89 | Upgrade |
Asset Writedown & Restructuring Costs | 0.47 | 0.47 | 6.92 | 0.9 | 2.53 | 0.26 | Upgrade |
Loss (Gain) From Sale of Investments | -3.68 | -3.68 | -0.95 | 0.06 | 0.31 | 0.23 | Upgrade |
Provision & Write-off of Bad Debts | 12.3 | 12.3 | 26.08 | 23.79 | 17.11 | 2.11 | Upgrade |
Other Operating Activities | 4.23 | 7.47 | -0.13 | -2.39 | 0.38 | 11.98 | Upgrade |
Change in Accounts Receivable | -37.38 | -37.38 | 9.84 | 135.21 | 47.24 | -306.89 | Upgrade |
Change in Inventory | -25.41 | -25.41 | -6.18 | 4.82 | 4.29 | 3.7 | Upgrade |
Change in Accounts Payable | 54.04 | 54.04 | 25.96 | 1 | 40.89 | 73.41 | Upgrade |
Change in Other Net Operating Assets | - | - | - | - | - | -0.88 | Upgrade |
Operating Cash Flow | 15.2 | 4.79 | 36.28 | 166.38 | 107.1 | -207.22 | Upgrade |
Operating Cash Flow Growth | -33.24% | -86.79% | -78.20% | 55.35% | - | - | Upgrade |
Capital Expenditures | -3.02 | -18.26 | -5.92 | -16.94 | -31.96 | -4.47 | Upgrade |
Sale of Property, Plant & Equipment | 0.02 | 0 | 17.72 | 0.33 | 0.07 | 0.01 | Upgrade |
Cash Acquisitions | -63.3 | 2.53 | - | - | - | - | Upgrade |
Investment in Securities | 0.76 | -98.19 | 0.95 | 0.49 | 0 | 12.47 | Upgrade |
Other Investing Activities | 6.04 | 5.59 | - | - | 1.74 | 0.28 | Upgrade |
Investing Cash Flow | -59.51 | -108.33 | 12.75 | -16.12 | -30.15 | 8.29 | Upgrade |
Short-Term Debt Issued | - | - | - | 75.14 | 55.86 | 243 | Upgrade |
Long-Term Debt Issued | - | 18 | 28 | - | - | - | Upgrade |
Total Debt Issued | - | 18 | 28 | 75.14 | 55.86 | 243 | Upgrade |
Short-Term Debt Repaid | - | -159.79 | -3.77 | -145 | -41.96 | -50.69 | Upgrade |
Long-Term Debt Repaid | - | -39.54 | -66.97 | -3.17 | -3.24 | - | Upgrade |
Total Debt Repaid | -164.33 | -199.33 | -70.74 | -148.17 | -45.2 | -50.69 | Upgrade |
Net Debt Issued (Repaid) | -164.33 | -181.33 | -42.74 | -73.03 | 10.66 | 192.31 | Upgrade |
Issuance of Common Stock | 1.25 | - | 273.7 | - | - | - | Upgrade |
Common Dividends Paid | - | -0.93 | -3.21 | -2.4 | -2.12 | -1.12 | Upgrade |
Other Financing Activities | 155.3 | -0.65 | -1.12 | -9.72 | 0.47 | 5.39 | Upgrade |
Financing Cash Flow | -7.78 | -182.91 | 226.63 | -85.15 | 9.02 | 196.58 | Upgrade |
Foreign Exchange Rate Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade |
Net Cash Flow | -52.09 | -286.45 | 275.66 | 65.11 | 85.97 | -2.35 | Upgrade |
Free Cash Flow | 12.18 | -13.47 | 30.36 | 149.44 | 75.14 | -211.69 | Upgrade |
Free Cash Flow Growth | 36.16% | - | -79.68% | 98.89% | - | - | Upgrade |
Free Cash Flow Margin | 9.71% | -10.02% | 22.19% | 74.59% | 47.97% | -120.58% | Upgrade |
Free Cash Flow Per Share | 0.04 | -0.04 | 0.10 | 0.48 | 0.24 | -0.78 | Upgrade |
Cash Interest Paid | - | - | - | - | 0.13 | - | Upgrade |
Cash Income Tax Paid | 12.07 | 10.71 | 18.25 | 9.24 | 16.06 | 7.8 | Upgrade |
Levered Free Cash Flow | -15.92 | -6.16 | 44.79 | 148.96 | 94.32 | -255.68 | Upgrade |
Unlevered Free Cash Flow | -15.38 | -5.24 | 51.71 | 157.03 | 104.3 | -253.17 | Upgrade |
Change in Working Capital | -9.65 | -9.65 | 28.94 | 141.25 | 91.79 | -231.86 | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.